impf-info.de

Nachdem Covid19 aus medizinischer Sicht "durch" ist, hier jetzt also wieder das Thema Impfen in ganzer Breite...
Font size: +

Covid19 - Risiko eines Guillain-Barré-Syndroms nach Virusvektor-Impfstoffen teilweise fast 8-fach erhöht

Auch wenn Covid19 medizinisch eigentlich durch ist: wenn das PEI und das RKI schon mal gemeinsam forschen und veröffentlichen...

In einer seiner berüchtigten "Observed-vs.-expected-Analysen" (die beim Thema Myokarditis nach mRNA-Impfstoffen teilweise sehr originelle Ergebnisse zeitigten) untersuchten Autoren beider Behörden das Risiko eines Guillain-Barré-Syndroms (GBS - einer potentiell lebensbedrohlichen Nervenlähmung) nach Covid-Impfstoffen.

Es zeigte sich ein - je nach Altersgruppe - bis zu fast 8-fach erhöhtes Risiko deines GBS nach den Vektor-Impfstoffen, bei allerdings aufgrund der geringen absoluten Fallzahlen sehr großen Vertrauensbereichen.

Eurosurveillance | Rare cases of Guillain-Barré syndrome after COVID-19 vaccination, Germany, December 2020 to August 2021

Background Guillain-Barré syndrome (GBS) has been associated with vaccination against COVID-19. Aim We aimed to compare clinical characteristics and analyse excess GBS cases following administration of different COVID-19 and influenza vaccines in Germany versus the expected numbers estimated from pre-pandemic background incidence rates. Methods We analysed safety surveillance data reported to the German national competent authority between 27 December 2020 and 31 August 2021. GBS cases were validated according to Brighton Collaboration (BC) criteria. We conducted observed vs expected (OvE) analyses on cases fulfilling BC criteria levels 1 to 4 for all four European Medicines Agency-approved COVID-19 vaccines and for influenza vaccines. Results A total of 214 GBS cases after COVID-19 vaccination had been reported, of whom 156 were eligible for further analysis. Standardised morbidity ratio estimates 3–42 days after vaccination were 0.34 (95% confidence interval (CI): 0.25–0.44) for Comirnaty, 0.38 (95% CI: 0.15–0.79) for Spikevax, 3.10 (95% CI: 2.44–3.88) for Vaxzevria, 4.16 (95% CI: 2.64–6.24) for COVID-19 Vaccine Janssen and 0.60 (95% CI: 0.35–0.94) for influenza vaccines. Bilateral facial paresis was reported in 19.7% and 26.1% of the 156 GBS cases following vaccination with Vaxzevria and COVID-19 Vaccine Janssen, respectively, and only in 6% of cases exposed to Comirnaty. Conclusion Three and four times more GBS cases than expected were reported after vaccination with Vaxzevria and COVID-19 Vaccine Janssen, respectively, therefore GBS might be an adverse event of vector-based vaccines. Bifacial paresis was more common in cases with GBS following vaccination with vector-based than mRNA COVID-19 vaccines.
Gürtelrose - verringert die Impfung das Risiko ein...
Influenza - aktuelle mRNA-Impfstoff-Kandidaten zu ...

By accepting you will be accessing a service provided by a third-party external to https://impf-info.de/